Abstract |
The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. Recently, selective serotonin reuptake inhibitors ( SSRIs) have been used more frequently. In the present study, the efficacy and side-effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared. The 71 patients diagnosed with SP according to DSM-III-R were randomly assigned to two subgroups; citalopram (n = 36) or moclobemide (n = 35). The study was an 8-week, randomized, open-label, rater-blinded, parallel-group trial. All patients were assessed by Hamilton anxiety rating (HAM-A), Liebowitz social anxiety (LSAS), clinical global impression-severity of illness (CGI-SI) and clinical global impression-improvement (CGI-I) scales. There was a similar percentage of responders ( citalopram 75%, n = 27 and moclobemide 74.3%, n = 26), with a >50% or greater reduction in LSAS total score and ratings of "very much" or "much improved" on the CGI-I. None of the patients withdrew from the study. The results of the present study suggest that citalopram has shown promising results in patients with SP.
|
Authors | Murad Atmaca, Murat Kuloglu, Ertan Tezcan, Ahmet Unal |
Journal | Human psychopharmacology
(Hum Psychopharmacol)
Vol. 17
Issue 8
Pg. 401-5
(Dec 2002)
ISSN: 0885-6222 [Print] England |
PMID | 12457375
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright 2002 John Wiley & Sons, Ltd. |
Chemical References |
- Monoamine Oxidase Inhibitors
- Serotonin Uptake Inhibitors
- Citalopram
- Moclobemide
|
Topics |
- Adolescent
- Adult
- Citalopram
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Moclobemide
(adverse effects, therapeutic use)
- Monoamine Oxidase Inhibitors
(adverse effects, therapeutic use)
- Phobic Disorders
(drug therapy, psychology)
- Psychiatric Status Rating Scales
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
|